Yonsei University · Medicine
Professor Jae-Hoon Kim's research lab specializes in ovarian cancer biomarker discovery and molecular oncology, focusing on identifying and validating novel diagnostic and prognostic markers such as osteopontin, cyclin-dependent kinase 1 (Cdk1), and epithelial cell adhesion molecule (Ep-CAM). The lab employs a multidisciplinary approach combining tissue microarray analysis, immunohistochemistry, real-time PCR, and ELISA to investigate the subcellular localization and clinical relevance of these proteins in epithelial ovarian cancer. A key research direction involves understanding the functional and prognostic significance of cytoplasmic Cdk1, which has been linked to poor survival outcomes. The lab also explores autoantibodies against tumor-associated antigens as potential non-invasive serum biomarkers.
Figures are computed from collected data and may differ slightly.
Our findings provide evidence for an association between levels of a biomarker, osteopontin, and ovarian cancer and suggest that future research assessing its clinical usefulness would be worthwhile.
Cyclin dependent kinase 1 (Cdk1) have previously reported correlation with cancer growth and a key regulator for cell cycle. Mostly, Cdk1's function of nucleus for cell cycle is well known to be associated with cancer, but cytoplasmic Cdk1's traits are not clearly identified, yet. We revealed that tissue microarray blocks of epithelial ovarian cancer (n = 249) showed increased level of cytoplasmic Cdk1 (p < 0.001), but not in nucleus (p = 0.192) of histologic cell type independently. On survival
The epithelial cell adhesion molecule (Ep-CAM) exhibited an ovarian cancer:normal human ovarian surface epithelium ratio of 444. For validation studies, real-time quantitative PCR analysis and immunohistochemistry were performed in normal and malignant ovarian epithelial cell lines and tissues. To evaluate the potential of the Ep-CAM autoantibody as a tumor marker, we examined the amount of Ep-CAM autoantibody in serum samples obtained from ovarian cancer patients and normal controls by an ELISA
Open papers in the app to read, cite, and organize with AI.
